Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted gene silencing using RGD-labeled chitosan nanoparticles.
Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Han HD, et al. Among authors: shen d. Clin Cancer Res. 2010 Aug 1;16(15):3910-22. doi: 10.1158/1078-0432.CCR-10-0005. Epub 2010 Jun 10. Clin Cancer Res. 2010. PMID: 20538762 Free PMC article.
Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Hu W, et al. Cancer Res. 2011 Sep 15;71(18):6030-9. doi: 10.1158/0008-5472.CAN-10-2719. Epub 2011 Jul 27. Cancer Res. 2011. PMID: 21795478 Free PMC article.
Editor's Note: Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles.
Han HD, Mangala LS, Lee JW, Shahzad MMK, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Han HD, et al. Among authors: shen d. Clin Cancer Res. 2021 Aug 1;27(15):4453. doi: 10.1158/1078-0432.CCR-21-2119. Clin Cancer Res. 2021. PMID: 34341058 No abstract available.
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. McLaughlin P, et al. Among authors: shen d. J Clin Oncol. 2023 Jan 10;41(2):154-162. doi: 10.1200/JCO.22.02403. J Clin Oncol. 2023. PMID: 36603541 Clinical Trial.
5,470 results